How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/moderate-to-severe-crohn-s-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Moderate to severe Crohn's disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Moderate to severe Crohn's disease (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Moderate to severe Crohn's disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Etrasimod	etrasimod	Pfizer	Sphingosine 1-phosphate receptor modulator	Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5	2023-01-01
tumor necrosis factor inhibitors (TNFi)	tumor-necrosis-factor-inhibitors-tnfi	Pfizer	biologic	tumor necrosis factor
TNF Inhibitor	tnf-inhibitor	Pfizer	Monoclonal Antibody	TNF-alpha
Chronic- PF-06480605 50 mg SC Q4W	chronic-pf-06480605-50-mg-sc-q4w	Pfizer	JAK inhibitor	JAK pathway
Velsipity	Etrasimod Arginine	Pfizer Inc.	Sphingosine 1-phosphate receptor modulator	Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5
Induction- PF-06480605 150 mg SC Q4W	induction-pf-06480605-150-mg-sc-q4w	Pfizer	JAK inhibitor	JAK pathway
Infliximab [infliximab biosimilar 3]	infliximab-infliximab-biosimilar-3	Pfizer	monoclonal antibody	tumor necrosis factor-alpha (TNF-alpha)
Chronic- PF-06480605 150 mg SC Q4W	chronic-pf-06480605-150-mg-sc-q4w	Pfizer	Janus kinase inhibitor	JAK1 and JAK2 enzymes
Induction- PF-06480605 450 mg SC Q4W	induction-pf-06480605-450-mg-sc-q4w	Pfizer	small molecule	IL-17 receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 8 drugs in Moderate to severe Crohn's disease
Pfizer Inc. · 1 drug in Moderate to severe Crohn's disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Moderate to severe Crohn's disease:

Cite this brief

Drug Landscape (2026). Moderate to severe Crohn's disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/moderate-to-severe-crohn-s-disease. Accessed 2026-06-10.

Moderate to severe Crohn's disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing